This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Relmada Therapeutics’s 8K filing here.
About Relmada Therapeutics
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Featured Articles
- Five stocks we like better than Relmada Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- What does consumer price index measure?
- MarketBeat Week in Review – 02/03 – 02/07
